December 10, 2019. The benefit Vernakalant for rapid conversion of recent-onset Afib might possibly provide to a subset of patients does not outweigh the serious risks associated with it.
Read More »On Medical Treatments & Products
NCHR Comments on Abuse Deterrent Formulations for Stimulant Medications
November 19, 2019. If FDA approves abuse deterrent formulations, the label should clearly describe the exact property demonstrated in studies.
Read More »NCHR Testimony on Research Needed on Immunological Responses to Metal in Implants
November 13, 2019. Dr. Diana Zuckerman describes the types of research needed to reduce harm from the metal and other substances in implanted devices, including joint replacements, cardiac implants, mesh, reproductive devices, and many other types of implants.
Read More »NCHR Testimony on Empagliflozin to Improve Glycemic Control
November 13, 2019. The data on Empagliflozin for managing Type 1 Diabetes is limited and it is not clear if the small improvement seen in the clinical trial is clinically meaningful for patients.
Read More »NCHR Testimony on Vascepa to Reduce Risk for Cardiovascular Events
November 14, 2019. Drugs to help reduce the risk of cardiovascular events save lives. The REDUCE-IT study provides encouraging data that AMR101 [Vascepa (icosapent ethyl) ] may help, but there are some important concerns that must be addressed before approval.
Read More »